Latest Entry: American Pravda and New York's Sixth Crime Family     Latest Comments: Talk Back Here

« Under Iran's 'divinely ordained justice', girls as young as nine are charged with 'moral crimes'. The best that they can hope for is to die by hanging | Main | On "A View from the eye of the storm" »

December 21, 2004

NEJM early release correspondence regarding valdecoxib (Bextra)

Topics: Clinical Pharmacology

20/12/2004. NEJM. (NEJM published early online on December 17, 2004)   

As a result of Pfizer's announcement that celecoxib has been shown to increase the risk of MI, the NEJM has published a letter regarding valdecoxib early. In it, the correspondents recommend that valdecoxib should not be prescribed except in extraordinary circumstances. This recommendation is based on the long delay between the initial evidence of the cardiotoxicity of rofecoxib and its withdrawal, recent studies demonstrating the cardiotoxicity of valdecoxib in high-risk patients, the availability of other therapies not currently known to have cardiovascular risks, and the lack of compelling evidence of countervailing benefits. The correspondents state that they believe this restriction should remain in effect until there are better safety data for valdecoxib.
Read all of the NEJM article .....

Posted by Hyscience at December 21, 2004 3:30 AM



Articles Related to Clinical Pharmacology: